References
- O‘Dwyer PJ , CatalanoRB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol.24 , 4534–4538 (2006).
- Han JY , LimHS, ShinES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24 , 2237–2244 (2006).
- Han JY , LimHS, YooYK et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110 , 138–147 (2007).
- Han JY , LimHS, LeeSY, KimHT, LeeJS. Influence of the organic anion transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer59 , 69–75 (2008).
- Innocenti F , UndeviaSD, IyerL et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22 , 1382–1388 (2004).
- de Jong FA , Scott-HortonTJ, KroetzDL et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81 , 42–49 (2007).
- Schellens JH , MaliepaardM, ScheperRJ et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann. NY Acad. Sci. 922 , 188–194 (2000).
- Han JY , ShinES, LeeYS et al. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer. Pharmacogenomics J. doi:10.1038/tpj.24. (2012) (Epub ahead of print).
- Giovannetti E , ToffalorioF, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? Pharmacogenomics13(9) , 1073–1086 (2012).
References
- Muggia FM . Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin. Oncol.16(2 Suppl. 5) , S7–S13 (1989).
- Mukherjea D , RybakLP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics12(7) , 1039–1050 (2011).
- Jiang J , LiangX, ZhouX, HuangR, ChuZ, ZhanQ. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol. Biol. Rep.39 , 6933–6942 (2012).
- Lord RV , BrabenderJ, GandaraD et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8 , 2286–2291 (2002).
- Noordhuis P , LaanAC, van de Born K, Losekoot N, Kathmann I, Peters GJ. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem. Pharmacol.76 , 53–61 (2008).
- Safaei R , HowellSB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol.53 , 13–23 (2005).
- Zhang S , LovejoyKS, ShimaJE et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66 , 8847–8857 (2006).
- Xu X , RenH, ZhouB et al. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer 77(2) , 438–442 (2012).
- Gao R , ReeceK, SissungT et al. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat. Res. 708 , 21–27 (2011).
- Ross CJ , Katzov-EckertH, DubéMP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41 , 1345–1349 (2009).
- Suk R , GurubhagavatulaS, ParkS et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res. 11 , 1534–1538 (2005).
- Brock PR , KnightKR, FreyerDR et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J. Clin. Oncol. 30 , 2408–2417 (2012).
- van der Vijgh WJ , PetersGJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin. Oncol.21(5 Suppl. 11) , S2–S7 (1994).